|Bid||35.98 x 400|
|Ask||36.99 x 100|
|Day's Range||35.33 - 36.54|
|52 Week Range||20.68 - 41.20|
|PE Ratio (TTM)||-14.34|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Valeant Pharmaceuticals International, Inc. (VRX) announced encouraging results from the long-term phase III extension study, AMAGINE-2 on psoriasis drug Siliq.
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
Shares of Intercept Pharmaceuticals (ICPT) have plunged 37% in the year so far due to safety issues regarding approved drug Ocaliva.
Allergan plc (AGN) announced that the FDA has accepted the new drug application (NDA) for ulipristal acetate, for the treatment of abnormal uterine bleeding in women with uterine fibroids.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ACADIA Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACAD-US. Comparing the performance and risk of ACADIA Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Mallinckrodt plc (MNK) announced that it will initiate a new phase IV study on H.P. Acthar Gel as a therapy option in patients with symptomatic sarcoidosis.
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.
With a balanced take on many newsworthy items regarding ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) released Wednesday, Leerink reiterated its Market Perform rating on the shares of the company. At time ...
Acadia briefly rallied, then dipped Thursday, after winning breakthrough approval for its dementia drug.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) stock initially jumped above $41 per share on Thursday after the FDA granted Breakthrough Designation to the company’s dementia-related psychosis drug candidate ...
ACADIA Pharmaceuticals' (ACAD) Nuplazid granted Breakthrough Therapy Designation for dementia-related psychosis. A phase III study for the same was also initiated.
Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.
Acadia popped 6% late Wednesday after the FDA granted its dementia drug breakthrough designation just as the drug begins a Phase 3 trial.
Acadia Pharmaceuticals Inc. shares rose in the extended session Wednesday after the biotech company said the Food and Drug Administration granted its dementia-related psychosis treatment a special designation ...
Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.